Free Shipping All Orders From 200 Limited Time Offer
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Kaletra

Kaletra

Customer rating: 4.9 out of 5
Availability: In Stock 56 packs
Active ingredient: Ritonavir, Lopinavir

Kaletra is FDA approved for the treatment of HIV-1 infection in adult and pediatric patients. Kaletra is a combination of two medications, lopinavir and ritonavir, and is now available in generic.

We accept:
VISA
MasterCard
PayPal
SEPA
Discover
Amex
BTC
USDT
Delivery options:
EMS
$29.95
Delivery period: 3-8 days
Tracking# available in 3 days
Airmail
$12.95
Delivery period: 14-21 days
Tracking# available in 14 days

Kaletra 250mg

Package Per pill Total price Save Order
250mg × 60 Pills $4.09 $245.16 FreeTrackable Delivery -
250mg × 120 Pills $3.79 $455.01 FreeTrackable Delivery $36.00
250mg × 180 Pills $3.69 $664.88 FreeTrackable Delivery $72.00
250mg × 240 Pills $3.64 $874.73 FreeTrackable Delivery $108.00
250mg × 300 Pills $3.62 $1,084.59 FreeTrackable Delivery $141.00
250mg × 360 Pills $3.60 $1,294.44 FreeTrackable Delivery $176.40

Package Example

Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents

Front view
Front view
Side view
Side view
Back view
Back view

Kaletra (lopinavir/ritonavir) is prescribed, in combination with other antiretroviral agents, for the treatment of HIV-1 infections in adults and pediatric patients over the age of 14.

Kaletra is available in both oral solution and tablet form. However its generic, lopinavir/ritonavir, is only available as a 160 ml bottle of oral solution.

Overdosage

Overdoses with KALETRA oral solution have been reported. One of these reports described fatal cardiogenic shock in a 2.1 kg infant who received a single dose of 6.5 mL of KALETRA oral solution (520 mg lopinavir, approximately 10-fold above the recommended lopinavir dose) nine days prior. The following events have been reported in association with unintended overdoses in preterm neonates: complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure. Healthcare professionals should be aware that KALETRA oral solution is highly concentrated and therefore, should pay special attention to accurate calculation of the dose of KALETRA, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors and overdose. This is especially important for infants and young children.

KALETRA oral solution contains approximately 42% (v/v) ethanol and approximately 15% (w/v) propylene glycol. Ingestion of the product over the recommended dose by an infant or a young child could result in significant toxicity and could potentially be lethal.

Human experience of acute overdosage with KALETRA is limited. Treatment of overdose with KALETRA should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with KALETRA. If indicated, elimination of unabsorbed drug should be achieved by gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since lopinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. However, dialysis can remove both ethanol and propylene glycol in the case of overdose with KALETRA oral solution.

Storage

  • Store KALETRA oral solution in a refrigerator, between 36°F to 46°F (2°C to 8°C). KALETRA oral solution that is kept refrigerated may be used until the expiration date printed on the label.
  • KALETRA oral solution that is stored at room temperature (less than 77°F or 25°C) should be used within 2 months.
  • Keep KALETRA oral solution away from high heat.
  • Throw away any medicine that is out of date or that you no longer need.

Safety information


Warnings

Risk Of Serious Adverse Reactions Due To Drug Interactions

Initiation of KALETRA, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving KALETRA, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of KALETRA, respectively. These interactions may lead to:

  • Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.
  • Clinically significant adverse reactions from greater exposures of KALETRA.
  • Loss of therapeutic effect of KALETRA and possible development of resistance.

Disclaimer

The information on this page is not intended to be a substitute for professional medical advice. Do not use this information to diagnose or treat your problem without consulting your doctor.

Side effects


The following adverse reactions are discussed in greater detail in other sections of the labeling.

  • QT Interval Prolongation, PR Interval Prolongation
  • Drug Interactions
  • Pancreatitis
  • Hepatotoxicity

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions In Adults

The safety of KALETRA has been investigated in about 2,600 patients in Phase II-IV clinical trials, of which about 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, KALETRA was used in combination with efavirenz or nevirapine.

In clinical studies the incidence of diarrhea in patients treated with either KALETRA capsules or tablets was greater in those patients treated once daily than in those patients treated twice daily. Any grade of diarrhea was reported by at least half of patients taking once daily Kaletra capsules or tablets. At the time of treatment discontinuation, 4.2-6.3% of patients taking once daily Kaletra and 1.8-3.7% of those taking twice daily Kaletra reported ongoing diarrhea.

Viagra
Bestsellers
Viagra Erectile Dysfunction
/ 4.9 out of 5
$0.24 Per pill
Delivery period: 3-8 days
|
Ships to United States
Add to cart
Super ED Trial Pack
Today’s sale
Super ED Trial Pack Erectile Dysfunction
/ 4.9 out of 5
$2.89 Per pill
Delivery period: 3-8 days
|
Ships to United States
Add to cart
Viagra Oral Jelly
Viagra Oral Jelly Erectile Dysfunction
/ 4.9 out of 5
$2.12 Per pill
Delivery period: 3-8 days
|
Ships to United States
Add to cart
Cialis Oral Jelly (Orange)
Cialis Oral Jelly (Orange) Erectile Dysfunction
/ 4.9 out of 5
$2.84 Per pill
Delivery period: 3-8 days
|
Ships to United States
Add to cart
Free Regmail
All Orders From $200
*Limited Time Offer
Free EMS Regmail
All Orders From $200
*Limited Time Offer
1M+ Customers
Quality, Privacy, Secure.
Very Low Prices
Best price in the world!
Fast Delivery
100% Guarantee. Free Airmail shipping.